^
    Back
    Association details:
    Biomarker:BRAF mutation + TERT −139CC>TT
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancers (Basel)
    Title:

    TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro

    Published date:
    05/24/2023
    Excerpt:
    In this cohort, 45 patients received a combination of BRAF and MEK inhibitors for metastatic BRAF-mutated melanoma….In patients with the wild-type TERT promoter, the median PFS was 13 months while it was 4.9, 5.3 and 3.9 months in patients with −124C > T, −146C > T and −138/−139CC > TT-mutated TERT promoter, respectively (p = 0.06).
    DOI:
    10.3390/cancers15112888